Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,086 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparative evaluation of bioequivalence of Gan & Lee glargine U300 and Toujeo® in Chinese healthy male participants.
Li X, He A, Liu B, Shan R, Zhu J, Li X, Xie T, Li Y, Chen M, Su H, Zhang C, Li L, Cheng D, Chen J, Wang Y, Su Y, Xu Y, Li Z, Zhou H, Chen W, Liu Y. Li X, et al. Among authors: su h, su y. Front Endocrinol (Lausanne). 2024 Aug 7;15:1407829. doi: 10.3389/fendo.2024.1407829. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39170740 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic evaluation of the new prolonged-release leuprorelin acetate microspheres for injection compared with Enantone® in healthy Chinese male volunteers.
Zhou H, Xie J, Zhu X, Li X, Yu X, Zhang Y, Su Y, He C, Zhu M, Li XL, Liu Y, Chen J, Cheng D, Chen M, Wang Y, Ge Q, Fan L, Wang Y, Shao Z, Liu B, Shan R, Dai X, Wang H, Wang H. Zhou H, et al. Among authors: su y. Expert Opin Drug Metab Toxicol. 2021 Sep;17(9):1149-1156. doi: 10.1080/17425255.2021.1948534. Epub 2021 Aug 10. Expert Opin Drug Metab Toxicol. 2021. PMID: 34372746 Free article. Clinical Trial.
A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin® in healthy Chinese male subjects.
Li H, Zhao X, Xie J, Zhu X, Su Y, He C, Ding J, Zhu M, Xu Y, Wang Y, Shan R, Liu B, Ding Y, Liu Y, Zhou H, Xie Y. Li H, et al. Among authors: su y. BMC Pharmacol Toxicol. 2023 May 27;24(1):36. doi: 10.1186/s40360-023-00673-y. BMC Pharmacol Toxicol. 2023. PMID: 37245022 Free PMC article. Clinical Trial.
Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumor.
Li H, Shan R, Ding J, Zhang J, Liu B, Ge Q, Cheng D, Li L, Zhang C, Su H, Li X, Li H, Ye J, Li H, Li F, Zhou H, Huo Q, Su Y. Li H, et al. Among authors: su h, su y. Expert Opin Drug Metab Toxicol. 2023 Dec;19(12):1015-1021. doi: 10.1080/17425255.2023.2292735. Epub 2024 Jan 12. Expert Opin Drug Metab Toxicol. 2023. PMID: 38059472 Free article. Clinical Trial.
Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects.
Xie J, Fan X, Su Y, Zhou H, Cao S, Zhu X, Zhu M, He C, Wang Y, Fan L, Ge Q, Zhu J, Liu B, Chen X, Xie Y, Ma L, Liu Y, Chen J, Wang H, Li Z. Xie J, et al. Among authors: su y. Clin Pharmacol Drug Dev. 2022 Nov;11(11):1273-1283. doi: 10.1002/cpdd.1136. Epub 2022 Jul 17. Clin Pharmacol Drug Dev. 2022. PMID: 35844038 Free PMC article. Clinical Trial.
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration.
Guo F, Liu B, Li X, Wang H, Zhu X, Su Y, He C, Zhu M, Ding J, Xu Y, Zhao X, Wang Y, Shan R, Zhu J, Xie J, Ge Q, Fan L, Ding Y, Xie Y, Zhang C, Li H, Wang H, Zhou H. Guo F, et al. Among authors: su y. Cancer Chemother Pharmacol. 2023 Feb;91(2):143-156. doi: 10.1007/s00280-022-04493-5. Epub 2022 Dec 27. Cancer Chemother Pharmacol. 2023. PMID: 36572783
Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial.
Zhou H, Zheng H, Peng Y, Su Y, Yu X, Wang W, Li S, Ding Y, Jiao S, Wang Y, Zhu X, Luo L, Dong Z, Liu L, Zhang F, Wu Q, Li J, Zhu F. Zhou H, et al. Among authors: su y. Front Immunol. 2024 Jun 6;15:1407826. doi: 10.3389/fimmu.2024.1407826. eCollection 2024. Front Immunol. 2024. PMID: 38903523 Free PMC article. Clinical Trial.
19,086 results
You have reached the last available page of results. Please see the User Guide for more information.